Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CIMA LABS Announces Date and Time Of Fourth Quarter Earnings Conference Call.


Business Editors

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 7, 2003

CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
. (Nasdaq:CIMA) today announced that its earnings conference call for the fourth quarter of 2002 ended December 31 will be held February 20 at 4:30 pm Eastern. The fourth quarter earnings release will be issued following the close of the market that day.

Investors can listen to a live webcast of the CIMA conference call at www.cimalabs.com or www.vcall.com. Listeners should go to one of these websites at least 15 minutes prior to the call to download To receive a file transmitted over a network. In any communications session, "download" means receive, and "upload" means send. The download/upload often implies a big/little scenario, in which data is being downloaded from the "big" server into the "little" user's computer.  and install any necessary audio software. The teleconference will be archived for 30 days.

A replay of the conference call will be available through February 27, by dialing 719-457-0820 and providing the 728482 confirmation code.

About CIMA LABS

CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient, which we frequently taste-mask, is formulated for·mu·late  
tr.v. for·mu·lat·ed, for·mu·lat·ing, for·mu·lates
1.
a. To state as or reduce to a formula.

b. To express in systematic terms or concepts.

c.
 into a new, orally disintegrating dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug.  that dissolves quickly in the mouth without chewing chewing
 or mastication

Up-and-down and side-to-side movements of the lower jaw, using the teeth to grind food for easier swallowing. During chewing, the tongue shapes food into a lump and saliva lubricates it for swallowing.
 or the need for water. CIMA's business involves a dual operating strategy. We develop and manufacture fast-dissolve versions of drugs for pharmaceutical company partners for whom we currently produce three branded prescription pharmaceuticals and three over-the-counter brands. CIMA is also developing proprietary products utilizing our fast-dissolve technologies, as well as our new OraVescent(R) enhanced absorption, transmucosal transmucosal /trans·mu·co·sal/ (trans?mu-ko´s'l) entering through, or across, a mucous membrane.
transmucosal,
 drug delivery system. CIMA's web site is www.cimalabs.com.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 7, 2003
Words:248
Previous Article:Millennium Partners Comments On Lawsuit Filed by Current MVC Management Team; Says MVC Management Is 'Bankrupt of Credibility'.
Next Article:MainConcept Announces Upcoming H.264 Codec; Professional Solution to Be Released in Q3.
Topics:



Related Articles
ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.
CIMA LABS Announces Date and Time Of Third Quarter Earnings Conference Call.
CIMA LABS Reports Record Third Quarter Operating Results; Full-Year 2002 Financial Guidance Increased Due to Outlook for Strong Fourth Quarter.
CIMA LABS Expects Fourth Quarter Earnings and Revenues Toward Upper End Of Previously-Reported Financial Guidance.
CIMA LABS Reports Record Fourth Quarter, Full-Year 2002 Operating Results.
CIMA LABS Announces Record Results for First Quarter of 2003; Revenues Nearly Double, Operating Income Rises More Than 150% Year-Over-Year.
CIMA LABS Announces Third-Quarter 2003 Financial Results; Product Sales More Than Double, Royalties Up 76 Percent Year-Over-Year.
CIMA LABS Announces Fourth-Quarter and Full-Year 2003 Financial Results; Company Reports Seventh Consecutive Quarter of Record Revenues.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles